Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

Videohaastattelu: lastensairaanhoitajan kokemuksia RSV-kaudelta

Lyso-Gb3가 파브리병 환자의 장기적인 임상사건 발생에 미치는 영향

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
Nowak A, et al. J Med Genet. 2022;59(3):287-293.

Clinical presentation and pathophysiology of Prurigo Nodularis (PN)

Explore the clinical presentation and pathophysiology of Prurigo Nodularis (PN), including its systemic inflammation, itching-scratching cycle, and effects on quality of life. Learn about the underlying mechanisms and treatment options for this chronic skin condition.

Toujeo'nun yeni QR Kodlu kutusuyla birlikte İnsülin Kalem Eğitimimiz Sizlerle!

Derma - Academy - Networking & best practice

Holistisk tilgang til patienten med type 2-inflammation.

Addressing Bone Disease in Lysosomal storage diseases

Dupilumab, graviditet och amning

Type 2 inflammation and CRSwNP

Studier på: Kronisk obstruktiv lungesygdom (KOL)

Hội Thảo Khoa Học Trực Tuyến: "Giá Trị Của Vắc-xin 6 Trong 1 Dạng Pha Sẵn Trong Chiến Lược Kiểm Soát Ho Gà Toàn Diện"

Guía de administración

Descargá la infografía relacionada con la dosificación de Beyfortus

Rezurock, el primer inhibidor selectivo de ROCK2

REZUROCK® es el primer inhibidor selectivo de ROCK2, diseñado para ayudar a los pacientes que diariamente ve en su práctica clínica1. Para pacientes adultos y pediátricos de 12 años con EICHc después del fracaso de al menos 2 líneas previas de terapia sistémica.1